(RTTNews) - CVRx, Inc. (CVRX) Tuesday announced today that it has received the FDA approval for revised Instructions For Use or IFU for Barostim incorporating key long-term clinical data from the BeAT-HF randomized clinical trial.
The commercial-stage medical device company said IFU is a post-market phase validation.
Barostim delivers Baroreflex Activation Therapy to improve patients' heart failure functional status, six-minute hall walk, and quality of life.
In the Pre-Market Phase, all effectiveness endpoints were previously met, however, in the Post-Market Phase effectiveness, primary endpoint of CV death and HF hospitalization was not met.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
